As of May 23, 2025, Trevena Inc (TRVN) reports a EV/EBITDA of -0.38.
EV/EBITDA evaluates a company's total value relative to its earnings before interest, taxes, depreciation, and amortization, useful for comparing firms with different capital structures.
Comparing Trevena Inc's EV/EBITDA to Peers
To better understand Trevena Inc's position, it's useful to compare its EV/EBITDA against industry peers. Below are selected comparisons:
| Company | EV/EBITDA |
|---|---|
| Trevena Inc (TRVN) | -0.38 |
| Abbvie Inc (ABBV) | 17.94 |
| Regeneron Pharmaceuticals Inc (REGN) | 14.71 |
| Amgen Inc (AMGN) | 14.64 |
| Gilead Sciences Inc (GILD) | 9.17 |
| Ovid Therapeutics Inc (OVID) | 0.16 |
Compared to its competitors, Trevena Inc's EV/EBITDA is about average compared to peers, indicating market valuation in line with industry expectations.